Table 3 Open in new tab Meta-regression...

Variables	Trials^a	MACE	CV death^b or MI
LDL-C reduction^c	12	0.71	0.49–0.94	0.01	26%	0.62	0.36–0.89	0.01	30%
TG reduction^c	10	0.96	0.53–1.40	0.86	36%	0.98	0.35–1.41	0.66	44%
HDL-C reduction^c	7	1.32	−0.44–3.07	0.72	50%	1.55	−0.67–3.77	0.62	60%
Baseline LDL-C^c	12	1.08	1.01–1.14	0.03	35%	1.09	1.01–1.17	0.03	43%
Mean age^d	12	1.10	1.00–1.20	0.06	42%	1.10	0.98–1.22	0.11	50%
Proportion of men^e	12	0.98	0.93–1.03	0.37	47%	0.97	0.91–1.03	0.33	52%
Proportion with DM^e	10	1.01	1.00–1.02	0.18	26%	1.01	1.00–1.03	0.14	37%
Publication year^d	12	1.04	1.01–1.08	0.03	34%	1.05	1.00–1.10	0.03	42%
Fibrate type	12			0.13	32%			0.08	31%
Bezafibrate		Reference			Reference
Clofibrate		0.89	0.76–1.08			0.93	0.71–1.14
Fenofibrate		0.98	0.78–1.17			1.00	0.77–1.23
Gemfibrozil		0.81	0.57–1.05			0.84	0.59–1.10
Pemafibrate		1.11	0.87–1.34			1.22	0.95–1.49

Variables

Trials^a

MACE

CV death^b or MI

95% CI

P-value

Residual heterogeneity (I²)

95% CI

P-value

Residual heterogeneity (I²)

LDL-C reduction^c

0.71

0.49–0.94

0.01

26%

0.62

0.36–0.89

0.01

30%

TG reduction^c

0.96

0.53–1.40

0.86

36%

0.98

0.35–1.41

0.66

44%

HDL-C reduction^c

1.32

−0.44–3.07

0.72

50%

1.55

−0.67–3.77

0.62

60%

Baseline LDL-C^c

1.08

1.01–1.14

0.03

35%

1.09

1.01–1.17

0.03

43%

Mean age^d

1.10

1.00–1.20

0.06

42%

1.10

0.98–1.22

0.11

50%

Proportion of men^e

0.98

0.93–1.03

0.37

47%

0.97

0.91–1.03

0.33

52%

Proportion with DM^e

1.01

1.00–1.02

0.18

26%

1.01

1.00–1.03

0.14

37%

Publication year^d

1.04

1.01–1.08

0.03

34%

1.05

1.00–1.10

0.03

42%

Fibrate type

0.13

32%

0.08

31%

Bezafibrate

Reference

Clofibrate

0.89

0.76–1.08

0.93

0.71–1.14

Fenofibrate

0.98

0.78–1.17

1.00

0.77–1.23

Gemfibrozil

0.81

0.57–1.05

0.84

0.59–1.10

Pemafibrate

1.11

0.87–1.34

1.22

0.95–1.49

Variables	Trials^a	MACE	CV death^b or MI
LDL-C reduction^c	12	0.71	0.49–0.94	0.01	26%	0.62	0.36–0.89	0.01	30%
TG reduction^c	10	0.96	0.53–1.40	0.86	36%	0.98	0.35–1.41	0.66	44%
HDL-C reduction^c	7	1.32	−0.44–3.07	0.72	50%	1.55	−0.67–3.77	0.62	60%
Baseline LDL-C^c	12	1.08	1.01–1.14	0.03	35%	1.09	1.01–1.17	0.03	43%
Mean age^d	12	1.10	1.00–1.20	0.06	42%	1.10	0.98–1.22	0.11	50%
Proportion of men^e	12	0.98	0.93–1.03	0.37	47%	0.97	0.91–1.03	0.33	52%
Proportion with DM^e	10	1.01	1.00–1.02	0.18	26%	1.01	1.00–1.03	0.14	37%
Publication year^d	12	1.04	1.01–1.08	0.03	34%	1.05	1.00–1.10	0.03	42%
Fibrate type	12			0.13	32%			0.08	31%
Bezafibrate		Reference			Reference
Clofibrate		0.89	0.76–1.08			0.93	0.71–1.14
Fenofibrate		0.98	0.78–1.17			1.00	0.77–1.23
Gemfibrozil		0.81	0.57–1.05			0.84	0.59–1.10
Pemafibrate		1.11	0.87–1.34			1.22	0.95–1.49

Table 3

Open in new tab

Meta-regression analysis for between-group differences in lipid profiles and major adverse cardiovascular outcomes

Variables	Trials^a	MACE				CV death^b or MI
Variables	Trials^a	RR	95% CI	P-value	Residual heterogeneity (I²)	RR	95% CI	P-value	Residual heterogeneity (I²)
LDL-C reduction^c	12	0.71	0.49–0.94	0.01	26%	0.62	0.36–0.89	0.01	30%
TG reduction^c	10	0.96	0.53–1.40	0.86	36%	0.98	0.35–1.41	0.66	44%
HDL-C reduction^c	7	1.32	−0.44–3.07	0.72	50%	1.55	−0.67–3.77	0.62	60%
Baseline LDL-C^c	12	1.08	1.01–1.14	0.03	35%	1.09	1.01–1.17	0.03	43%
Mean age^d	12	1.10	1.00–1.20	0.06	42%	1.10	0.98–1.22	0.11	50%
Proportion of men^e	12	0.98	0.93–1.03	0.37	47%	0.97	0.91–1.03	0.33	52%
Proportion with DM^e	10	1.01	1.00–1.02	0.18	26%	1.01	1.00–1.03	0.14	37%
Publication year^d	12	1.04	1.01–1.08	0.03	34%	1.05	1.00–1.10	0.03	42%
Fibrate type	12			0.13	32%			0.08	31%
Bezafibrate		Reference				Reference
Clofibrate		0.89	0.76–1.08			0.93	0.71–1.14
Fenofibrate		0.98	0.78–1.17			1.00	0.77–1.23
Gemfibrozil		0.81	0.57–1.05			0.84	0.59–1.10
Pemafibrate		1.11	0.87–1.34			1.22	0.95–1.49

Variables	Trials^a	MACE				CV death^b or MI
Variables	Trials^a	RR	95% CI	P-value	Residual heterogeneity (I²)	RR	95% CI	P-value	Residual heterogeneity (I²)
LDL-C reduction^c	12	0.71	0.49–0.94	0.01	26%	0.62	0.36–0.89	0.01	30%
TG reduction^c	10	0.96	0.53–1.40	0.86	36%	0.98	0.35–1.41	0.66	44%
HDL-C reduction^c	7	1.32	−0.44–3.07	0.72	50%	1.55	−0.67–3.77	0.62	60%
Baseline LDL-C^c	12	1.08	1.01–1.14	0.03	35%	1.09	1.01–1.17	0.03	43%
Mean age^d	12	1.10	1.00–1.20	0.06	42%	1.10	0.98–1.22	0.11	50%
Proportion of men^e	12	0.98	0.93–1.03	0.37	47%	0.97	0.91–1.03	0.33	52%
Proportion with DM^e	10	1.01	1.00–1.02	0.18	26%	1.01	1.00–1.03	0.14	37%
Publication year^d	12	1.04	1.01–1.08	0.03	34%	1.05	1.00–1.10	0.03	42%
Fibrate type	12			0.13	32%			0.08	31%
Bezafibrate		Reference				Reference
Clofibrate		0.89	0.76–1.08			0.93	0.71–1.14
Fenofibrate		0.98	0.78–1.17			1.00	0.77–1.23
Gemfibrozil		0.81	0.57–1.05			0.84	0.59–1.10
Pemafibrate		1.11	0.87–1.34			1.22	0.95–1.49

MACE, major adverse cardiovascular outcome; CV, cardiovascular; MI, myocardial infarction; RR, risk ratio; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; DM, diabetes mellitus.

^aNumber of trials with reported or imputed values for each variable, respectively.

^bAll-cause death used instead of cardiovascular death for the DAIS trial.

^cPer each 1 mmol/L decrease.

^dPer 10 year increase.

^ePer 10% increase.

This Feature Is Available To Subscribers Only